ADHD Medications Not Found to Impact Cardiovascular Disease Risk
December 5th 2022Study does not show a statistically significant association for specific cardiovascular outcomes related to cardiac arrest or arrhythmias, cerebrovascular diseases, or myocardial infarction associated with medications for attention-deficit hyperactivity disorder.
Read More
FDA Approves First-in-Class Microbiota-Based Live Biotherapeutic for C. Difficile Infection
December 1st 2022Live-jslm (Rebyota; Ferring Pharmaceuticals) is indicated for the prevention of recurring Clostridioides difficile infection among patients 18 years of age and older after an antibiotic treatment.
Read More